EUVIMEDEUVIMED entdecken
Crossref

Structure‐Atropisomer Stability Relationship in Selective MCL‐1 Inhibitors

Szabolcs Sipos, Barbara Balazs, Tamas Gati, Márton Csékei iD, Mihály Kováacs iD, Zoltan Szlavik, Attila Paczal, Balázs Bálint, James B Murray, James Davidson, Roderick E Hubbard, Gaëtane Le Toumelin-Braizat und 4 weitere

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Szabolcs Sipos und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servier Research Institute of Medicinal Chemistry, Zahony u. 7., 1031, Budapest, Hungary. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atropisomersm is an emerging feature in recent drug candidates due to the increasing complexity of the targeted protein surfaces. The developability of the drug candidates requires that their atropisomer interconversion is either fast or very slow at ambient temperature therefore the understanding and predictability of the isomerization rate is of great importance. Through a series of selective MCL‐1 inhibitors we studied how structural features influence the interconversion of atropisomers. Besides basic observations such as stability in solution, we also carried out NMR kinetics at varying temperatures and a quantum chemical assessment of the isomerization process. The results of our theoretical studies and experimental investigations matched nicely when it came to predicting the presence or absence of isomerization at ambient temperature. For certain compounds we also measured the rotational barrier that fitted nicely the predicted values. The better understanding of how structural elements impact atropisomer stability enables the more efficient optimization of this important feature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Cell Leukemia Sequence 1 ProteinHumansIsomerismStructure-Activity RelationshipMolecular StructureStereoisomerismKinetics

Stichwörter der Autor:innen

NMR spectroscopyactivation barrieratropisomerisomerizationquantumchemical calculations

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinMCL1 protein, human

Autor:innen und Institutionen

  • Servier Research Institute of Medicinal Chemistry, Zahony u. 7., 1031, Budapest, Hungary.
  • Department of Chemistry, Eszterházy Károly Catholic University, Leányka u. 6, 3300, Eger, Hungary.
  • Vernalis R&D, Granta Park, Great Abington, Cambridge, B21 6GB, UK.
  • Institute de Recherche Servier, 22 Route 128, 91190, Gif-sur-Yvette, France.
  • Present address: Pierre Fabre Laboratories, Toulouse, France.
  • Theoretical Chemistry Research Group, Institute of Organic Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar tudosok krt 2, 1117, Budapest, Hungary E-mail.

ORCID-Profile: Márton Csékei, Mihály Kováacs, András Stirling, András Kotschy

Zitieren

APA

Sipos, S., Balazs, B., Gati, T., Csékei, M., Kováacs, M., Szlavik, Z., Paczal, A., Bálint, B., Murray, J. B., Davidson, J., Hubbard, R. E., Le Toumelin-Braizat, G., Maragno, A. L., Geneste, O., Stirling, A., & Kotschy, A. (2025). Structure‐Atropisomer Stability Relationship in Selective MCL‐1 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202400970

Vancouver

Sipos S, Balazs B, Gati T, Csékei M, Kováacs M, Szlavik Z, et al. Structure‐Atropisomer Stability Relationship in Selective MCL‐1 Inhibitors. ChemMedChem. 2025. doi:10.1002/cmdc.202400970

BibTeX
@article{Sipos2025,
  author = {Sipos, Szabolcs and Balazs, Barbara and Gati, Tamas and Csékei, Márton and Kováacs, Mihály and Szlavik, Zoltan and Paczal, Attila and Bálint, Balázs and Murray, James B and Davidson, James and Hubbard, Roderick E and Le Toumelin-Braizat, Gaëtane and Maragno, Ana Leticia and Geneste, Olivier and Stirling, András and Kotschy, András},
  title = {Structure‐Atropisomer Stability Relationship in Selective MCL‐1 Inhibitors},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400970}
}
Kostenlos starten →